Tower Research Capital (TRC)’s Cidara Therapeutics CDTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-2,198
| Closed | -$486K | – | 5155 |
|
|
2025
Q4 | $486K | Buy |
2,198
+1,005
| +84% | +$162K | 0.01% | 841 |
|
|
2025
Q3 | $114K | Sell |
1,193
-363
| -23% | -$23.2K | ﹤0.01% | 1894 |
|
|
2025
Q2 | $75.8K | Buy |
1,556
+623
| +67% | +$15K | ﹤0.01% | 2614 |
|
|
2025
Q1 | $20.1K | Buy |
+933
| New | +$20.7K | ﹤0.01% | 2962 |
|
|
2024
Q4 | – | Sell |
-1,115
| Closed | -$12K | – | 5714 |
|
|
2024
Q3 | $12K | Buy |
1,115
+369
| +49% | +$4.43K | ﹤0.01% | 3629 |
|
|
2024
Q2 | $8.91K | Buy |
746
+294
| +65% | +$4.02K | ﹤0.01% | 4304 |
|
|
2024
Q1 | $8.32K | Sell |
452
-169
| -27% | -$2.43K | ﹤0.01% | 4038 |
|
|
2023
Q4 | $9.86K | Buy |
621
+482
| +347% | +$7.74K | ﹤0.01% | 4335 |
|
|
2023
Q3 | $2.62K | Sell |
139
-449
| -76% | -$8.81K | ﹤0.01% | 5131 |
|
|
2023
Q2 | $13.3K | Buy |
588
+578
| +5,780% | +$13.6K | ﹤0.01% | 3788 |
|
|
2023
Q1 | $0 | Sell |
10
-1,062
| -99% | -$30.1K | ﹤0.01% | 5846 |
|
|
2022
Q4 | $16K | Buy |
1,072
+431
| +67% | +$5.14K | ﹤0.01% | 3325 |
|
|
2022
Q3 | $8K | Sell |
641
-470
| -42% | -$6.49K | ﹤0.01% | 4764 |
|
|
2022
Q2 | $11K | Buy |
1,111
+681
| +158% | +$8.41K | ﹤0.01% | 4357 |
|
|
2022
Q1 | $7K | Sell |
430
-165
| -28% | -$2.8K | ﹤0.01% | 4701 |
|
|
2021
Q4 | $15K | Buy |
595
+351
| +144% | +$10.9K | ﹤0.01% | 3977 |
|
|
2021
Q3 | $11K | Buy |
+244
| New | +$9.27K | ﹤0.01% | 4211 |
|
|
2021
Q2 | – | Sell |
-530
| Closed | -$28K | – | 5496 |
|
|
2021
Q1 | $28K | Buy |
530
+56
| +12% | +$2.77K | ﹤0.01% | 3603 |
|
|
2020
Q4 | $19K | Sell |
474
-1,166
| -71% | -$58K | ﹤0.01% | 3896 |
|
|
2020
Q3 | $93K | Buy |
1,640
+262
| +19% | +$18.5K | ﹤0.01% | 3193 |
|
|
2020
Q2 | $102K | Buy |
+1,378
| New | +$89.3K | ﹤0.01% | 2435 |
|
|
2019
Q4 | – | Sell |
-34
| Closed | -$1K | – | 3602 |
|
|
2019
Q3 | $1K | Buy |
34
+30
| +750% | +$1.01K | ﹤0.01% | 3825 |
|
|
2019
Q2 | $0 | Sell |
4
-637
| -99% | -$26.5K | ﹤0.01% | 3720 |
|
|
2019
Q1 | $34K | Buy |
641
+574
| +857% | +$31.5K | ﹤0.01% | 1965 |
|
|
2018
Q4 | $3K | Sell |
67
-699
| -91% | -$49.9K | ﹤0.01% | 3154 |
|
|
2018
Q3 | $68K | Buy |
766
+521
| +213% | +$46K | 0.01% | 1565 |
|
|
2018
Q2 | $26K | Buy |
245
+77
| +46% | +$7.27K | ﹤0.01% | 2261 |
|
|
2018
Q1 | $14K | Buy |
168
+134
| +394% | +$18.3K | ﹤0.01% | 2327 |
|
|
2017
Q4 | $5K | Buy |
34
+22
| +183% | +$3.34K | ﹤0.01% | 2861 |
|
|
2017
Q3 | $2K | Sell |
12
-14
| -54% | -$1.99K | ﹤0.01% | 3547 |
|
|
2017
Q2 | $4K | Buy |
+26
| New | +$3.59K | ﹤0.01% | 2075 |
|
|
2016
Q4 | – | Sell |
-11
| Closed | -$2K | – | 3844 |
|
|
2016
Q3 | $2K | Sell |
11
-3
| -21% | -$693 | ﹤0.01% | 3034 |
|
|
2016
Q2 | $3K | Buy |
14
+11
| +367% | +$2.66K | ﹤0.01% | 3665 |
|
|
2016
Q1 | $1K | Sell |
3
-33
| -92% | -$7.61K | ﹤0.01% | 3649 |
|
|
2015
Q4 | $12K | Buy |
36
+22
| +157% | +$6.61K | ﹤0.01% | 1871 |
|
|
2015
Q3 | $3K | Buy |
14
+11
| +367% | +$3.15K | ﹤0.01% | 3101 |
|
|
2015
Q2 | $1K | Buy |
+3
| New | +$923 | ﹤0.01% | 3964 |
|
Tower Research Capital (TRC)'s CDTX Position: Q1 2026 in Review
Tower Research Capital (TRC) sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 2,198 shares — an estimated $486K sold.
Tower Research Capital (TRC) first reported a position in CDTX in Q2 2015 and held it in 37 quarters. The position peaked at $486K in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.
- Tower Research Capital (TRC) reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
- Tower Research Capital (TRC) sold 2,198 Cidara Therapeutics shares in Q1 2026, an estimated $486K.
- Tower Research Capital (TRC) first reported a position in Cidara Therapeutics in Q2 2015 and held it in 37 quarters.
- Tower Research Capital (TRC)'s Cidara Therapeutics position peaked at $486K in Q4 2025.
- 0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.